© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Flor M. Munoz, MD, MSc
Articles
Dosing Strategy and Final Pearls for Nirsevimab for RSV
September 18, 2023
Experts conclude their discussion on the efficacy and safety study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on possible dosing strategies and key takeaways from this study.
Adverse Events Observed in Study of Nirsevimab for RSV
September 18, 2023
Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.
Infant Weight and Efficacy Outcomes of Nirsevimab for RSV
September 18, 2023
Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.
RSV Strains and Nirsevimab for RSV
September 18, 2023
Experts discuss data relating to the strains of Respiratory Syncytial Virus (RSV) and how clinicians should consider them in relation to the efficacy of nirsevimab.
Time-To-Event Analysis and Discussion on the Efficacy Nirsevimab for RSV
September 18, 2023
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.
Data Review of Efficacy and Safety Study of Nirsevimab for RSV
September 18, 2023
Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.
Discussion of Study Patient Population on Nirsevimab for RSV
September 18, 2023
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the patient population of the safety and efficacy study on nirsevimab for Respiratory Syncytial Virus (RSV).
Study Background on Single-Dose Nirsevimab for RSV
September 18, 2023
Tina Tan, MD, FAAP, FIDSA, FPIDS, presents the background, objectives, and methods of a recent study on the efficacy and safety of nirsevimab for Respiratory Syncytial Virus (RSV) in late-preterm and term infants.
Prevalence and Clinical Gaps of RSV
September 18, 2023
Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the prevalence of Respiratory Syncytial Virus (RSV) and prior preventative gaps. They also discuss the recent FDA-approval of nirsevimab for late-preterm and term infants.
Introduction and Overview of RSV and Nirsevimab
September 18, 2023
Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, introduce the objectives of their discussion and background information on Respiratory Syncytial Virus (RSV) and nirsevimab.